| Budget Amount *help |
¥195,780,000 (Direct Cost: ¥150,600,000、Indirect Cost: ¥45,180,000)
Fiscal Year 2014: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2013: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2012: ¥43,680,000 (Direct Cost: ¥33,600,000、Indirect Cost: ¥10,080,000)
Fiscal Year 2011: ¥42,380,000 (Direct Cost: ¥32,600,000、Indirect Cost: ¥9,780,000)
Fiscal Year 2010: ¥44,200,000 (Direct Cost: ¥34,000,000、Indirect Cost: ¥10,200,000)
|
|---|
| Outline of Final Research Achievements |
We clarified the clinical and laboratory features of aquaporin (AQP) 4-antibody-positive neuromyelitis optica (NMO), and contributed to the new international consensus diagnostic criteria of NMO Spectrum Disorders (NMOSD), a wider clinical entity of NMO. We also revealed that AQP4-antibody-positve NMOSD is not a demyelinating disease like multiple sclerosis but an autoimmune astrocytopathic disease. Moreover, we discovered that a fraction of AQP4-antibody-negative NMOSD are positive for myelin oligodendrocyte glycoprotein (MOG)-antibody and those cases have some unique clinical features. Importantly, unlike AQP4-antibody-positive NMOSD, MOG-antibody-positive NMOSD appears to be a demyelinating disease.
|
